REDUX/PONDIMIN WITHDRAWALS PROVOKE QUESTIONS OF OFF-LABEL USE PROVISIONS IN FDA REFORM BILL; FEN-PHEN CITED IN KENNEDY ATTEMPT TO CHANGE DEVICE PROVISIONS